0.69407.50% ( -0.0563 )
Trading: Nov 10, 13:12:39 (EDT)Current ValuationThe current P/E ratio is -0.68, within the reasonable range, cheaper than 30.16% of the time in the past 5 years, and the industry ranks 178/607, the industry Median -1.88.
-0.685xP/E
$0.75Stock price
$-1.10Earnings per share
-0.685xP/E
Stock price$0.75Earnings per share$-1.10
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -1.18x
- Typical range
- -2.63x–-0.58x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
013263952
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
| Name/Symbol | |||
|---|---|---|---|
GILDUSGilead Sciences | -54.38x | 162.83% | $210.01B |
MRNAUSModerna | -38.51x | 3.57% | $107.39B |
CSLLYUSCSL Limited | -26.11x | -- | $67.34B |
NTRAUSNatera | -282.05x | 0.90% | $46.46B |
RVMDUSRevolution Medicines | -22.93x | 40.80% | $42.90B |
ROIVUSRoivant Sciences | -85.31x | 77.78% | $29.38B |
INSMUSInsmed | -42.06x | 74.47% | $25.47B |
BNTXUSBioNTech SE | -12.82x | 25.93% | $21.70B |
BBIOUSBridgebio Pharma | -25.64x | 30.83% | $15.18B |
SMMTUSSummit Therapeutics | -17.09x | 23.12% | $14.23B |
KYMRUSKymera Therapeutics | -33.04x | 8.74% | $11.55B |
BMRNUSBioMarin Pharma | -579.41x | 61.50% | $11.08B |
PCVXUSVaxcyte | -9.31x | 44.27% | $10.69B |
SYREUSSpyre Therapeutics | -46.21x | 59.92% | $10.35B |
MDGLUSMadrigal Pharma | -64.67x | 87.15% | $10.05B |
PRAXUSPraxis Precision Medicines | -25.86x | 3.20% | $9.30B |
TWSTUSTwist Bioscience | -65.17x | 28.63% | $8.91B |
RYTMUSRhythm Pharma | -39.84x | 51.65% | $7.90B |
ALKSUSAlkermes | -22,104.19x | 133.59% | $7.76B |
CYTKUSCytokinetics | -9.87x | 8.47% | $7.68B |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
